BIND Therapeutics Inc (BIND)

Etorro trading 970x250

About BIND Therapeutics Inc

BIND Therapeutics, Inc. is a clinical-stage nanomedicine platform company developing Accurins, its targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Its drug candidate, BIND-014, is in Phase II clinical trials for non-small cell lung cancer, or NSCLC, and metastatic castrate-resistant prostate cancer (mCRPC). Address:

BIND Therapeutics Inc News and around…

BIND Therapeutics Inc (BIND) is a NASDAQ Common Stock listed in ,

970x250